Seagen Inc.
SGENNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for SGEN. That does not mean none is planned.
Get an email about SGEN's next catalysts
Track Seagen (SGEN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Adcetris
Brentuximab Vedotin
Hodgkin Lymphoma
Enfortumab Vedotin
Renal Pelvis and Ureter Urothelial Carcinoma
sigvotatug vedotin
Carcinoma, Non-Small-Cell Lung
disitamab vedotin
Breast Neoplasms
vincristine
Anaplastic Large-Cell Lymphoma
Enfortumab vedotin (EV)
Bladder Cancer
tucatinib
Gastric Adenocarcinoma
Padcev
Enfortumab Vedotin
Urothelial Cancer
SEA-CD40
Melanoma
Tisotumab Vedotin (HuMax-TF-ADC)
Ovary Cancer
SGN-40 (anti-huCD40 mAb)
Leukemia, Lymphocytic, Chronic
Lintuzumab (SGN-33)
Acute Myeloid Leukemia
ladiratuzumab vedotin
Triple Negative Breast Neoplasms
SGN-15, Docetaxel
Non-Small Cell Lung Carcinoma
tisotumab vedotin
Ovarian Cancer
SGN-30
Large Cell Lymphoma
Adriamycin, vinblastine, and dacarbazine
Hodgkin Lymphoma
brentuximab vedotin (SGN-35)
Hodgkin's Lymphoma
Alpelisib
HER2-positive Metastatic Breast Cancer
Pertuzumab
Metastatic Breast Cancer With a Isolated Brain Progression
CHEP
Lymphoma
Dacarbazine(R)
Stage II Childhood Hodgkin Lymphoma
Adriamycin
Hodgkin Lymphoma
Tukysa
Tucatinib
HER2+ Breast Cancer
SGN-40
Lymphoma, Large B-Cell, Diffuse
SGN-30 (monoclonal antibody)
Hodgkin Disease
SGN-15 (cBR96-doxorubicin immunoconjugate)
Prostatic Neoplasms
SGN-15
Carcinoma, Non-Small-Cell Lung
SGN-30 (anti-CD30 mAb)
Anaplastic Large-Cell Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Adcetris Brentuximab Vedotin | Approved | Hodgkin Lymphoma | Orphan | - |
Enfortumab Vedotin | Phase 3 | Renal Pelvis and Ureter Urothelial Carcinoma | - | - |
sigvotatug vedotin | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
disitamab vedotin | Phase 3 | Breast Neoplasms | - | - |
vincristine | Phase 3 | Anaplastic Large-Cell Lymphoma | - | - |
Enfortumab vedotin (EV) | Phase 3 | Bladder Cancer | - | - |
tucatinib | Phase 3 | Gastric Adenocarcinoma | - | Patent 2038 |
Padcev Enfortumab Vedotin | Phase 3 | Urothelial Cancer | Fast TrackBreakthrough | - |
SEA-CD40 | Phase 2 | Melanoma | - | - |
Tisotumab Vedotin (HuMax-TF-ADC) | Phase 2 | Ovary Cancer | - | - |
SGN-40 (anti-huCD40 mAb) | Phase 2 | Leukemia, Lymphocytic, Chronic | - | - |
Lintuzumab (SGN-33) | Phase 2 | Acute Myeloid Leukemia | - | - |
ladiratuzumab vedotin | Phase 2 | Triple Negative Breast Neoplasms | - | - |
SGN-15, Docetaxel | Phase 2 | Non-Small Cell Lung Carcinoma | - | Patent 2036 |
tisotumab vedotin | Phase 2 | Ovarian Cancer | - | - |
SGN-30 | Phase 2 | Large Cell Lymphoma | - | - |
Adriamycin, vinblastine, and dacarbazine | Phase 2 | Hodgkin Lymphoma | - | - |
brentuximab vedotin (SGN-35) | Phase 2 | Hodgkin's Lymphoma | - | - |
Alpelisib | Phase 2 | HER2-positive Metastatic Breast Cancer | - | - |
Pertuzumab | Phase 2 | Metastatic Breast Cancer With a Isolated Brain Progression | - | - |
CHEP | Phase 2 | Lymphoma | - | - |
Dacarbazine(R) | Phase 2 | Stage II Childhood Hodgkin Lymphoma | - | - |
Adriamycin | Phase 2 | Hodgkin Lymphoma | - | - |
Tukysa Tucatinib | Phase 2 | HER2+ Breast Cancer | Fast TrackBreakthrough | Patent 2038 |
SGN-40 | Phase 2 | Lymphoma, Large B-Cell, Diffuse | - | - |
SGN-30 (monoclonal antibody) | Phase 2 | Hodgkin Disease | - | - |
SGN-15 (cBR96-doxorubicin immunoconjugate) | Phase 2 | Prostatic Neoplasms | - | - |
SGN-15 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
SGN-30 (anti-CD30 mAb) | Phase 2 | Anaplastic Large-Cell Lymphoma | - | - |
Urothelial Cancer
1 drug in this indication
HER2+ Breast Cancer
1 drug in this indication
Triple Negative Breast Neoplasms
1 drug in this indication
Hodgkin Lymphoma
1 drug in this indication
Leukemia, Lymphocytic, Chronic
1 drug in this indication
Lymphoma, Large B-Cell, Diffuse
1 drug in this indication
Hodgkin Disease
1 drug in this indication
Prostatic Neoplasms
1 drug in this indication
Gastric Adenocarcinoma
1 drug in this indication
Large Cell Lymphoma
1 drug in this indication
Lymphoma, B-Cell
1 drug in this indication
Ovary Cancer
1 drug in this indication
Non-Small Cell Lung Carcinoma
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Melanoma
1 drug in this indication
Acute Myeloid Leukemia
1 drug in this indication
Anaplastic Large-Cell Lymphoma
1 drug in this indication
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Disease, Hodgkin
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Seagen Inc.'s drug pipeline?→
CatalystAlert tracks 29 drug candidates in Seagen Inc.'s (SGEN) pipeline across Phase 3, Phase 2, Approved. Its lead program is Adcetris (Approved). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Seagen Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Seagen Inc. (SGEN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SGEN biotech catalysts?→
Add SGEN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Seagen Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.